- Home
- RCMT vs NTHI Comparison
RCMT vs NTHI Comparison
Compare RCMT & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RCMT | NTHI |
|---|---|---|
| Founded | 1971 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.0M | 178.4M |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | RCMT | NTHI |
|---|---|---|
| Price | $30.44 | $4.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $36.00 | $15.00 |
| AVG Volume (30 Days) | ★ 79.0K | 54.5K |
| Earning Date | 04-03-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.38 | N/A |
| EPS | ★ 2.14 | N/A |
| Revenue | ★ $186,737,000.00 | N/A |
| Revenue This Year | $11.89 | N/A |
| Revenue Next Year | $12.46 | N/A |
| P/E Ratio | $14.72 | ★ N/A |
| Revenue Growth | ★ 5.83 | N/A |
| 52 Week Low | $16.90 | $3.20 |
| 52 Week High | $32.28 | $12.99 |
Technical Indicators
Market Signals| Indicator | RCMT | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 72.92 | 21.20 |
| Support Level | $17.77 | N/A |
| Resistance Level | N/A | $5.82 |
| Average True Range (ATR) | 1.35 | 0.53 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 83.97 | 5.80 |
Price Performance
Historical ComparisonAbout RCMT RCM Technologies Inc.
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).